Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (61-70 of 222) with videos related to

Pageof 23
Sort By:
Molecular Cell|March 4, 2008
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box moduleDavid Komander, Christopher J Lord, Hartmut Scheel, et al.
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
Open Biology|July 27, 2022
Opinion: PARP inhibitors in cancer-what do we still need to know?Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, et al.
Nature Reviews. Cancer|August 11, 2021
Targeting the DNA damage response in immuno-oncology: developments and opportunitiesRoman M Chabanon, Mathieu Rouanne, Christopher J Lord, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCRSaira Khalique, Stephen J Pettitt, Ger Kelly, et al.
Nature Reviews. Clinical Oncology|February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentSophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
The EMBO Journal|February 2, 2012
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerRachel Brough, Ilirjana Bajrami, Radost Vatcheva, et al.
Oncotarget|January 8, 2015
The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signallingNeil Rajan, Richard J R Elliott, Alice Smith, et al.
Cell Reports|February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerAgnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
EMBO Molecular Medicine|January 6, 2010
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2Sarah A Martin, Afshan McCarthy, Louise J Barber, et al.
Pageof 23

Showing results (61-70 of 222) with videos related to

Sort By:
Pageof 23
Molecular Cell|March 4, 2008
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box moduleDavid Komander, Christopher J Lord, Hartmut Scheel, et al.
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
Open Biology|July 27, 2022
Opinion: PARP inhibitors in cancer-what do we still need to know?Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, et al.
Nature Reviews. Cancer|August 11, 2021
Targeting the DNA damage response in immuno-oncology: developments and opportunitiesRoman M Chabanon, Mathieu Rouanne, Christopher J Lord, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCRSaira Khalique, Stephen J Pettitt, Ger Kelly, et al.
Nature Reviews. Clinical Oncology|February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentSophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
The EMBO Journal|February 2, 2012
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerRachel Brough, Ilirjana Bajrami, Radost Vatcheva, et al.
Oncotarget|January 8, 2015
The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signallingNeil Rajan, Richard J R Elliott, Alice Smith, et al.
Cell Reports|February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerAgnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
EMBO Molecular Medicine|January 6, 2010
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2Sarah A Martin, Afshan McCarthy, Louise J Barber, et al.
Pageof 23